Crow Scott J, Mitchell James E, Roerig James D, Steffen Kristine
Department of Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota 55454-1495, USA.
Int J Eat Disord. 2009 Jan;42(1):1-8. doi: 10.1002/eat.20576.
To review selected issues regarding the development of drug treatments for anorexia nervosa (AN).
The existing pharmacotherapy literature for AN is reviewed, and the theoretical and practical considerations are discussed.
A very wide variety of drugs have been examined in AN, generally with negative results. There are a number of potential reasons for this finding, including compliance, nutritional deficits, selection of the wrong targets or the wrong outcome measures, use of monotherapy, lack of animal models, or factors intrinsic to AN.
Pharmacotherapy provides little benefit in the treatment of AN at present. Several strategies might lead to the identification of more effective agents, including new measurement strategies, identification of novel pharmacologic targets, and consideration of a clinical trials network.
回顾有关神经性厌食症(AN)药物治疗发展的特定问题。
回顾了现有的关于AN的药物治疗文献,并讨论了理论和实践方面的考虑因素。
在AN中已经对非常多种类的药物进行了研究,总体结果为阴性。这一发现有许多潜在原因,包括依从性、营养缺乏、选择错误的靶点或错误的结局测量指标、使用单一疗法、缺乏动物模型或AN本身的内在因素。
目前药物治疗在AN的治疗中益处不大。几种策略可能会有助于识别更有效的药物,包括新的测量策略、识别新的药理学靶点以及考虑建立一个临床试验网络。